Allogene Therapeutics (ALLO) Stock Forecast & Price Target

$2.70

+0.09 (+3.45%)

(As of 10/4/2024 ET)

Allogene Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 11 Analyst Ratings

Sell
0

Hold
3

Buy
8

Based on 11 Wall Street analysts who have issued ratings for Allogene Therapeutics in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 11 analysts, 3 have given a hold rating, and 8 have given a buy rating for ALLO.

Consensus Price Target

$9.96
268.72% Upside

According to the 11 analysts' twelve-month price targets for Allogene Therapeutics, the average price target is $9.96. The highest price target for ALLO is $14.00, while the lowest price target for ALLO is $4.60. The average price target represents a forecasted upside of 268.72% from the current price of $2.70.

Get the Latest News and Ratings for ALLO and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Allogene Therapeutics and its competitors.

ALLO Analyst Ratings Over Time

Type	Current Forecast 10/7/23 to 10/6/24	1 Month Ago 9/7/23 to 9/6/24	3 Months Ago 7/9/23 to 7/8/24	1 Year Ago 10/7/22 to 10/7/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	8 Buy rating(s)	8 Buy rating(s)	7 Buy rating(s)	8 Buy rating(s)
Hold	3 Hold rating(s)	3 Hold rating(s)	3 Hold rating(s)	2 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$9.96	$9.96	$9.95	$16.19
Forecasted Upside	268.72% Upside	313.09% Upside	344.20% Upside	434.40% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

Next opportunity for crypto millions (Ad)

October isn't just another month in crypto. It's the launchpad for what could be the most explosive bull run in history. And I've found the rocket fuel… One coin is quietly positioning itself to outperform the entire market. The signs are everywhere…

Go here to discover the coin that could define this historic bull run with gains kicking off this mo

ALLO Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

ALLO Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Allogene Therapeutics Stock vs. The Competition

Type	Allogene Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	2.73	2.79	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	268.72% Upside	10,592.03% Upside	7.02% Upside
News Sentiment Rating	Neutral News See Recent ALLO News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
8/15/2024	HC Wainwright 2 of 5 stars		Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $9.00	+300.00%
8/9/2024	Citigroup 3 of 5 stars		Boost Target	Buy ➝ Buy	$7.00 ➝ $8.00	+244.83%
8/9/2024	Truist Financial 2 of 5 stars		Reiterated Rating	Buy ➝ Buy	$17.00 ➝ $14.00	+493.22%
8/8/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$13.00 ➝ $11.00	+345.34%
8/8/2024	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$35.00 ➝ $14.00	+466.80%
5/31/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Overweight	$11.00	+347.15%
Get the Latest News and Ratings for ALLO and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Allogene Therapeutics and its competitors with MarketBeat's FREE daily newsletter.
5/14/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Hold ➝ Hold	$4.40 ➝ $4.60	+58.62%
3/15/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Outperform	$10.00	+130.41%
2/27/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$9.00 ➝ $8.00	+54.44%
1/5/2024	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Neutral
1/5/2024	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Market Perform
4/17/2023	EF Hutton Acquisition Co. I Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Buy	$15.00	+209.92%
3/22/2023	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Corwin Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
3/21/2023	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Market Perform	$6.00	+11.73%
3/1/2023	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy	$35.00 ➝ $31.00	+388.19%
3/1/2023	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$18.00 ➝ $15.00	+136.22%
1/6/2023	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Neutral ➝ Outperform	$12.00	+106.54%
12/12/2022	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Underperform	$24.00 ➝ $9.00	+2.74%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 02:23 AM ET.

ALLO Forecast - Frequently Asked Questions

: According to the research reports of 11 Wall Street equities research analysts, the average twelve-month stock price forecast for Allogene Therapeutics is $9.96, with a high forecast of $14.00 and a low forecast of $4.60.
: 11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Allogene Therapeutics in the last year. There are currently 3 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ALLO shares.
: According to analysts, Allogene Therapeutics's stock has a predicted upside of 268.72% based on their 12-month stock forecasts.
: Allogene Therapeutics has been rated by research analysts at Canaccord Genuity Group, Citigroup, HC Wainwright, Oppenheimer, and Truist Financial in the past 90 days.
: Analysts like Allogene Therapeutics less than other "medical" companies. The consensus rating score for Allogene Therapeutics is 2.73 while the average consensus rating score for "medical" companies is 2.79. Learn more on how ALLO compares to other companies.